| Title: | Genetic variability in sodium-glucose cotransporter 2 and glucagonlike peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice |
|---|
| Authors: | ID Tonin, Gašper (Author)
ID Goričar, Katja (Author)
ID Blagus, Tanja (Author)
ID Janež, Andrej (Author)
ID Dolžan, Vita (Author)
ID Klen, Jasna (Author) |
|---|
| Files: |  PDF - Presentation file, download (740,73 KB)
MD5: AAA9580D23D5BF0745FF4656A8250ED4
 URL - Source URL, visit https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1547920/abstract
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | We investigated the impact of genetic polymorphisms in the GLP1R and SLC5A2 genes on the response to treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists and sodium-glucose co-transporter-2 (SLGT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) in everyday clinical practice.In our prospective interventional cohort open-label real-world genetic association study (DRKS-ID: DRKS00034478, https://drks.de/search/en/trial/DRKS00034478), we enrolled 161 clinically well-defined T2DM patients who received SGLT2 inhibitors and/or GLP-1R agonists alongside other medications for 3-6 months. The study's primary outcomes (HbA1c, body mass, and blood pressure) were measured before the treatment and at the follow-up at 3-6 months. GLP1R rs6923761, rs10305420, and SLC5A2 rs9934336 genotypes were determined by competitive allelespecific polymerase chain reaction. In patients receiving GLP-1R agonists, we analyzed the effect of GLP1R polymorphisms on the patients' response to treatment, while in patients receiving SGLT2 inhibitors, we analyzed the impact of the SLC5A2 polymorphism on the treatment effect.Treatment with prescribed antihyperglycemic drugs improved all primary outcomes (p < 0.050). The normal GLP1R rs6923761 G allele was associated with a greater reduction in HbA1c with GLP-1R agonists treatment than the polymorphic A allele in the dominant model (p = 0.029).The prevalent polymorphic A allele of GLP1R rs6923761 polymorphism was associated with the clinically relevant lower glycemic response to GLP-1R agonists. The described impact extends to everyday clinical practice, indicating that knowledge of these genetic polymorphisms could facilitate the development of targeted and personalized therapy in managing T2DM. |
|---|
| Keywords: | polymorphism, type 2 diabetes, treatment response |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2025 |
|---|
| Number of pages: | str. 1-11 |
|---|
| Numbering: | Vol. 16 |
|---|
| PID: | 20.500.12556/DiRROS-24135  |
|---|
| UDC: | 616.379 |
|---|
| ISSN on article: | 1664-2392 |
|---|
| DOI: | 10.3389/fendo.2025.1547920 |
|---|
| COBISS.SI-ID: | 240748547 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 29. 6. 2025;
|
|---|
| Publication date in DiRROS: | 17.11.2025 |
|---|
| Views: | 238 |
|---|
| Downloads: | 118 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
